BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 19720904)

  • 21. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
    Daver N; Shastri A; Kadia T; Newberry K; Pemmaraju N; Jabbour E; Zhou L; Pierce S; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2014 Sep; 38(9):1126-9. PubMed ID: 25047979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
    Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
    N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
    Pardanani A; Gotlib JR; Jamieson C; Cortes JE; Talpaz M; Stone RM; Silverman MH; Gilliland DG; Shorr J; Tefferi A
    J Clin Oncol; 2011 Mar; 29(7):789-96. PubMed ID: 21220608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
    Nijhof IS; Franssen LE; Levin MD; Bos GMJ; Broijl A; Klein SK; Koene HR; Bloem AC; Beeker A; Faber LM; van der Spek E; Ypma PF; Raymakers R; van Spronsen DJ; Westerweel PE; Oostvogels R; van Velzen J; van Kessel B; Mutis T; Sonneveld P; Zweegman S; Lokhorst HM; van de Donk NWCJ
    Blood; 2016 Nov; 128(19):2297-2306. PubMed ID: 27647864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study].
    Xu ZF; Qin TJ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):24-28. PubMed ID: 30704224
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
    Witzig TE; Luigi Zinzani P; Habermann TM; Tuscano JM; Drach J; Ramchandren R; Kalayoglu Besisik S; Takeshita K; Casadebaig Bravo ML; Zhang L; Fu T; Goy A
    Am J Hematol; 2017 Oct; 92(10):E575-E583. PubMed ID: 28699256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.
    Tefferi A; Lasho TL; Mesa RA; Pardanani A; Ketterling RP; Hanson CA
    Leukemia; 2007 Aug; 21(8):1827-8. PubMed ID: 17460705
    [No Abstract]   [Full Text] [Related]  

  • 28. Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study.
    Qu S; Xu Z; Qin T; Li B; Pan L; Chen J; Yan X; Wu J; Zhang Y; Zhang P; Gale RP; Xiao Z
    Hematol Oncol; 2022 Oct; 40(4):787-795. PubMed ID: 35609279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.
    Madan RA; Karzai FH; Ning YM; Adesunloye BA; Huang X; Harold N; Couvillon A; Chun G; Cordes L; Sissung T; Beedie SL; Dawson NA; Theoret MR; McLeod DG; Rosner I; Trepel JB; Lee MJ; Tomita Y; Lee S; Chen C; Steinberg SM; Arlen PM; Gulley JL; Figg WD; Dahut WL
    BJU Int; 2016 Oct; 118(4):590-7. PubMed ID: 26780387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.
    Mesa RA; Elliott MA; Schroeder G; Tefferi A
    Mayo Clin Proc; 2004 Jul; 79(7):883-9. PubMed ID: 15244384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Research and Applications Progress of Lenalidomide for Myelofibrosis--Review].
    Fan WJ; Wu T; Chen JW; Bai H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1854-1857. PubMed ID: 30501733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B
    J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
    Zweegman S; van der Holt B; Mellqvist UH; Salomo M; Bos GM; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden AW; Deenik W; Gruber A; Coenen JL; Plesner T; Klein SK; Tanis BC; Szatkowski DL; Brouwer RE; Westerman M; Leys MR; Sinnige HA; Haukås E; van der Hem KG; Durian MF; Mattijssen EV; van de Donk NW; Stevens-Kroef MJ; Sonneveld P; Waage A
    Blood; 2016 Mar; 127(9):1109-16. PubMed ID: 26802176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of ruxolitinib for myelofibrosis.
    Santos FP; Verstovsek S
    Expert Opin Pharmacother; 2014 Jul; 15(10):1465-73. PubMed ID: 24856675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).
    Raza A; Galili N; Mulford D; Smith SE; Brown GL; Steensma DP; Lyons RM; Boccia R; Sekeres MA; Garcia-Manero G; Mesa RA
    J Hematol Oncol; 2012 Apr; 5():18. PubMed ID: 22546242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.
    Baz R; Patel M; Finley-Oliver E; Lebovic D; Hussein MA; Miller KC; Wood M; Sher T; Lee K; Chanan-Khan AA
    Leuk Lymphoma; 2010 Jun; 51(6):1015-9. PubMed ID: 20367570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
    Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
    Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.